Kidney Disease: Improving Global Outcomes (KDIGO) CD-MBD Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease – mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1. doi: 10.1016/j.kisu.2017.04.001..
DOI: 10.1016/j.kisu.2017.04.001
Pike J.W., Christakos S. Biology and mechanisms of action of the vitamin D hormone. Endocrinol Metab Clin North Am. 2017;46(4):815–843. doi: 10.1016/j.ecl.2017.07.001..
DOI: 10.1016/j.ecl.2017.07.001
Christakos S., Dhawan P., Verstuyf A., Verlinden L., Carmeliet G. Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects. Physiol Rev. 2016;96(1):365–408. doi: 10.1152/physrev.00014.2015..
DOI: 10.1152/physrev.00014.2015
Пигарова Е.А., Рожинская Л.Я., Белая Ж.Е., Дзеранова Л.К., Каронова Т.Л., Ильин А.В. и др. Клинические рекомендации Российской ассоциации эндокринологов по диагностике, лечению и профилактике дефицита витамина D у взрослых. Проблемы эндокринологии. 2016;62(4):60–84. doi: 10.14341/probl201662460-84..
DOI: 10.14341/probl201662460-84
Zittermann A., Ernst J.B., Birschmann I., Dittrich M. Effect of vitamin D or activated vitamin D on circulating 1,25-dihydroxyvitamin D concentrations: a systematic review and metaanalysis of randomized controlled trials. Clin Chem. 2015;61(12):1484–1494. doi: 10.1373/clinchem.2015.244913..
DOI: 10.1373/clinchem.2015.244913
Haussler M.R., Haussler C., Jurutka P., Thompson P., Hsieh J.-C., Remus L. et al. The vitamin D hormone and its nuclear receptor: molecular actions and disease states. J Endocrinol. 1997;154(S):S57–S73. Available at: https://pubmed.ncbi.nlm.nih.gov/9379138/https://pubmed.ncbi.nlm.nih.gov/9379138/
Haussler M.R., Haussler C., Jurutka P., Thompson P., Hsieh J.-C., Remus L. et al. The vitamin D hormone and its nuclear receptor: molecular actions and disease states. J Endocrinol. 1997;154(S):S57–S73. Available at: https://pubmed.ncbi.nlm.nih.gov/9379138/https://pubmed.ncbi.nlm.nih.gov/9379138/
Bikle D.D. Extraskeletal actions of vitamin D. Ann NY Acad Sci. 2016;1376(1):29–52. doi: 10.1111/nyas.13219..
DOI: 10.1111/nyas.13219
Nigwekar S.U., Tamez H., Thadhani R.I. Vitamin D and chronic kidney disease – mineral bone disease (CKD–MBD). BoneKey Rep. 2014;3:498. doi: 10.1038/bonekey.2013.232..
DOI: 10.1038/bonekey.2013.232
Portillo M.R., Rodríguez-Ortiz M.E. Secondary hyperparthyroidism: pathogenesis, diagnosis, preventive and therapeutic strategies. Rev Endocr Metab Disord. 2017;18(1):79–95. doi: 10.1007/s11154-017-9421-4..
DOI: 10.1007/s11154-017-9421-4
Chesney R.W. Interactions of vitamin D and the proximal tubule. Pediatr Nephrol. 2016;31(1):7–14. doi: 10.1007/s00467-015-3050-5..
DOI: 10.1007/s00467-015-3050-5
Nitta K., Nagano N., Tsuchiya K. Fibroblast growth factor 23/klotho axis in chronic kidney disease. Nephron Clin Pract. 2014;128(1–2):1–10. doi: 10.1159/000365787..
DOI: 10.1159/000365787
Franca Gois P.H., Wolley M., Ranganathan D., Seguro A.C. Vitamin D deficiency in chronic kidney disease: Recent evidence and controversies. Int J Environl Res Public Health. 2018;15(8):1773. doi: 10.3390/ijerph15081773..
DOI: 10.3390/ijerph15081773
Brandi L., Egfjord M., Olgaard K. Pharmacokinetics of 1,25(OH)2D3 and 1α(OH)D3 in normal and uraemic men. Nephrol Dialysis Transpl. 2002;17(5):829–842. doi: 10.1093/ndt/17.5.829..
DOI: 10.1093/ndt/17.5.829
Brown A.J., Finch J., Slatopolsky E. Differential effects of 19-nor-1,25-dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3 on intestinal calcium and phosphate transport. J Lab Clinl Med. 2002;139(5):279–284. doi: 10.1067/mlc.2002.122819..
DOI: 10.1067/mlc.2002.122819
Slatopolsky E., Cozzolino M., Lu Y., Finch J., Dusso A., Staniforth M. et al. Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia. Kidney Int. 2003;63(6):2020–2027. doi: 10.1046/j.1523-1755.2003.00029.x..
DOI: 10.1046/j.1523-1755.2003.00029.x
Coyne D.W., Grieff M., Ahya S.N., Giles K., Norwood K., Slatopolsky E. Differential effects of acute administration of 19-Nor-1, 25-dihydroxyvitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. Am J Kidney Dis. 2002;40(6):1283–1288. doi: 10.1053/ajkd.2002.36899..
DOI: 10.1053/ajkd.2002.36899
Negrea L. Active vitamin D in chronic kidney disease: getting right back where we started from? Kidney Dis (Basel). 2019;5(2):59–68. doi: 10.1159/000495138..
DOI: 10.1159/000495138
Robinson D.M., Scott L.J. Paricalcitol: a review of its use in the management of secondary hyperparathyroidism. Drugs. 2005;65(4):559–576. doi: 10.2165/00003495-200565040-00008..
DOI: 10.2165/00003495-200565040-00008
Liu Y., Liu L.-Y., Jia Y., Wu M.-Y., Sun Y.-Y., Ma F.-Z. Efficacy and safety of paricalcitol in patients undergoing hemodialysis: a meta-analysis. Drug Des Devel Ther. 2019;13:999–1009. doi: 10.2147/DDDT.S176257..
DOI: 10.2147/DDDT.S176257
Geng X., Shi E., Wang S., Song Y. A comparative analysis of the efficacy and safety of paricalcitol versus other vitamin D receptor activators in patients undergoing hemodialysis: A systematic review and meta-analysis of 15 randomized controlled trials. Plos One. 2020;15(5):e0233705. doi: 10.1371/journal.pone.0233705..
DOI: 10.1371/journal.pone.0233705
Xie Y., Su P., Sun Y., Zhang H., Zhao R., Li L. et al. Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials. BMC Nephrol. 2017;18(1):1–9. doi: 10.1186/s12882-017-0691-6..
DOI: 10.1186/s12882-017-0691-6
Dobrez D.G., Mathes A., Amdahl M., Marx S.E., Melnick J.Z., Sprague S.M. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant. 2004;19(5):1174–11781. doi: 10.1093/ndt/gfh123..
DOI: 10.1093/ndt/gfh123
Teng M., Wolf M., Lowrie E., Ofsthun N., Lazarus J.M., Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Eng J Med. 2003;349(5):446–456. doi: 10.1056/NEJMoa022536..
DOI: 10.1056/NEJMoa022536
Teng M., Wolf M., Ofsthun M.N., Lazarus J.M., Hernán M.A., Camargo C.A., Thadhani R. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol. 2005;16(4):1115–1125. doi: 10.1681/ASN.2004070573..
DOI: 10.1681/ASN.2004070573
Coyne D.W., Goldberg S., Faber M., Ghossein C., Sprague S.M. A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3–4 CKD. Clin J Am Soc Nephrol. 2014;9(9): 1620–1626. doi: 10.2215/CJN.10661013..
DOI: 10.2215/CJN.10661013
Tentori F., Hunt W., Stidley C., Rohrscheib M., Bedrick E., Meyer K. et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 2006;70(10):1858–1865. doi: 10.1038/sj.ki.5001868..
DOI: 10.1038/sj.ki.5001868
Coyne D., Acharya M., Qiu P., Abboud H., Batlle D., Rosansky S. et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis. 2006;47(2):263–276. doi: 10.1053/j.ajkd.2005.10.007..
DOI: 10.1053/j.ajkd.2005.10.007
Мокрышева Н., Маганева И. Минерально-костные нарушения у пациентов с хронической болезнью почек и сахарным диабетом: реальные возможности кардио- и нефропротекции. Медицинский совет. 2018(4):60–65. doi: 10.21518/2079-701X-2018-4-60-65..
DOI: 10.21518/2079-701X-2018-4-60-65
Wu-Wong J.R., Nakane M., Ma J. Vitamin D analogs modulate the expression of plasminogen activator inhibitor-1, thrombospondin-1 and thrombomodulin in human aortic smooth muscle cells. J Vasc Res. 2007;44(1):11–18. doi: 10.1159/000097812..
DOI: 10.1159/000097812
Thadhani R., Appelbaum E., Pritchett Y., Chang Y., Wenger J., Tamez H. et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA. 2012;307(7):674–684. doi: 10.1001/jama.2012.120..
DOI: 10.1001/jama.2012.120
Wang AY.-M., Fang F., Chan J., Wen Y.-Y., Qing S., Chan IH.-S. et al. Effect of paricalcitol on left ventricular mass and function in CKD – the OPERA trial. J Am Soc Nephrol. 2014;25(1):175–186. doi: 10.1681/ASN.2013010103..
DOI: 10.1681/ASN.2013010103
Li X.H., Feng L., Yang Z.H., Liao Y.H. Effect of active vitamin D on cardiovascular outcomes in predialysis chronic kidney diseases: A systematic review and meta‐analysis. Nephrology (Carlton). 2015;20(10):706–714. doi: 10.1111/nep.12505..
DOI: 10.1111/nep.12505
Cheng J., Zhang W., Zhang X., Li X., Chen J. Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol. 2012;7(3):391–400. doi: 10.2215/CJN.03000311..
DOI: 10.2215/CJN.03000311
Tan X., Li Y., Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol. 2006;17(12):3382–3393. doi: 10.1681/ASN.2006050520..
DOI: 10.1681/ASN.2006050520
De Zeeuw D., Agarwal R., Amdahl M., Audhya P., Coyne D., Garimella T. et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet. 2010;376(9752):1543–1551. doi: 10.1016/S0140-6736(10)61032-X..
DOI: 10.1016/S0140-6736(10)61032-X
Joergensen C., Tarnow L., Goetze J., Rossing P. Vitamin D analogue therapy, cardiovascular risk and kidney function in people with Type 1 diabetes mellitus and diabetic nephropathy: a randomized trial. Diabetic Med. 2015;32(3):374–381. doi: 10.1111/dme.12606..
DOI: 10.1111/dme.12606
Santos R.D., Rossi A., Coyne D., Maw T.T. Management of post-transplant hyperparathyroidism and bone disease. Drugs. 2019;79(5):501–513. doi: 10.1007/s40265-019-01074-4..
DOI: 10.1007/s40265-019-01074-4
Bleskestad I.H., Bergrem H., Leivestad T., Hartmann A., Gøransson L.G. Parathyroid hormone and clinical outcome in kidney transplant patients with optimal transplant function. Clin Transplant. 2014;28(4):479–486. doi: 10.1111/ctr.12341..
DOI: 10.1111/ctr.12341
Park J.W., Bae E.H., Kim I.J., Ma S.K., Choi C., Lee J., Kim S.W. Paricalcitol attenuates cyclosporine-induced kidney injury in rats. Kidney Int. 2010;77(12):1076–1085. doi: 10.1038/ki.2010.69..
DOI: 10.1038/ki.2010.69
Trillini M., Cortinovis M., Ruggenenti P., Loaeza J.R., Courville K., Ferrer-Siles C. et al. Paricalcitol for secondary hyperparathyroidism in renal transplantation. J Am Soc Nephrol. 2015;26(5):1205–1214. doi: 10.1681/ASN.2013111185..
DOI: 10.1681/ASN.2013111185
Gonzalez E., Rojas-Rivera J., Polanco N., Morales E., Morales J.M., Egido J. et al. Effects of oral paricalcitol on secondary hyperparathyroidism and proteinuria of kidney transplant patients. Transplantation. 2013;95(7): e49–e52. doi: 10.1097/TP.0b013e3182855565..
DOI: 10.1097/TP.0b013e3182855565
Pihlstrøm H.K., Gatti F., Hammarström C., Eide I.A., Kasprzycka M., Wang J. et al. Early introduction of oral paricalcitol in renal transplant recipients. An open‐label randomized study. Transplant Int. 2017;30(8):827–840. doi: 10.1111/tri.12973..
DOI: 10.1111/tri.12973
Amer H., Griffin M., Stegall M., Cosio F., Park W., Kremers W. et al. Oral paricalcitol reduces the prevalence of posttransplant hyperparathyroidism: results of an open label randomized trial. Am J Transplant. 2013;13(6):1576–1585. doi: 10.1111/ajt.12227..
DOI: 10.1111/ajt.12227
Kaminska D., Tyran B., Mazanowska O., Rabczynski J., Szyber P., Patrzalek D. et al. Cytokine gene expression in kidney allograft biopsies after donor brain death and ischemia-reperfusion injury using in situ reversetranscription polymerase chain reaction analysis. Transplantation. 2007;84(9):1118–1124. doi: 10.1097/01.tp.0000287190.86654.74..
DOI: 10.1097/01.tp.0000287190.86654.74
Del Prete D., Ceol M., Anglani F., Vianello D., Tiralongo E., Valente M. et al. Early activation of fibrogenesis in transplanted kidneys: a study on serial renal biopsies. Exp Mol Pathol. 2009;87(2):141–145. doi: 10.1016/j.yexmp.2009.07.004..
DOI: 10.1016/j.yexmp.2009.07.004
Oblak M., Mlinšek G., Kandus A., Buturović-Ponikvar J., Arnol M. Effects of paricalcitol on biomarkers of inflammation and fibrosis in kidney transplant recipients: results of a randomized controlled trial. Clin Nephrol. 2017 Suppelment 1;88(13):119–125. doi: 10.5414/CNP88FX26..
DOI: 10.5414/CNP88FX26
Levin A., Bakris G., Molitch M., Smulders M., Tian J., Williams L., Andress D.L. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney int. 2007;71(1):31–38. doi: 10.1038/sj.ki.5002009..
DOI: 10.1038/sj.ki.5002009